L-Carnitine

L-carnitine is an amino-acid derivative — synthesized in the body from the amino acids lysine and methionine — not a peptide, protein, or hormone. It plays a central role in energy metabolism by helping transport fatty acids into the mitochondria, where they are burned for fuel.

L-carnitine is obtained from the diet (notably red meat) and made endogenously, and it is also sold as a supplement and used clinically. Its most clearly established medical role is in treating genuine carnitine deficiency, while its popular use for fat loss and energy in otherwise healthy people rests on weaker evidence.

L-carnitine does not act as a signaling peptide; its function is metabolic and well defined biochemically. High-level themes include:

• Serving as a carrier that shuttles long-chain fatty acids across the mitochondrial membrane
• Enabling those fatty acids to undergo beta-oxidation for energy production
• Contributing to the handling of metabolic byproducts within the mitochondria

While this transport role is well established, whether supplementing extra L-carnitine meaningfully increases fat burning in people who are not deficient is a separate and less settled question.

The clearest medical use of L-carnitine is in genuine carnitine deficiency — whether primary (genetic) or secondary to certain conditions or treatments — where supplementation addresses a real deficit. In these contexts it may be used under medical supervision, including in injectable forms.

Outside of deficiency, L-carnitine is widely marketed as a supplement for fat metabolism, energy, and exercise. These popular uses are more expansive than the evidence supports, and regulatory treatment differs between a supplement and a clinically administered product.

L-carnitine does not appear anywhere on the WADA Prohibited List, and oral or dietary intake carries no anti-doping consequence. The exposure is entirely in delivery. Section M2.2, Chemical and Physical Manipulation, prohibits "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations." Since IV L-carnitine is typically given in a saline bag well above 100 mL, an infusion in a clinic, a hotel room or a recovery lounge crosses the line even though nothing prohibited is in the bag.

A 2025-26 case shows how expensive that distinction is. Adane Anmaw Mengesha, a 22-year-old Ethiopian track and field athlete, accepted a five-year period of ineligibility beginning 5 November 2025. No prohibited substance was involved: she received intravenous infusions exceeding the 100 mL / 12-hour limit outside a hospital setting, and then committed a second, far more serious violation — tampering — by submitting falsified documents claiming the infusions had been administered at a hospital in Addis Ababa. The sanction was reduced from six years to five under the early-admission provision (USADA announcement).

M2.2 is a Specified Method, so a genuine, well-documented medical infusion is arguable and a retroactive TUE is possible. The Mengesha case escalated because of the paperwork, not the carnitine.

Reported experiences with oral use include nonspecific gastrointestinal symptoms such as nausea, cramping, or a fishy body odor at higher intakes. Injectable and intravenous use carries the additional risks inherent to any injection or infusion procedure.

There has also been scientific discussion about carnitine metabolism, gut bacteria, and a metabolite called TMAO in the context of cardiovascular research — an area that remains debated. As always, product quality, individual risk factors, and professional guidance matter, and high-level summaries are not a substitute for rigorous evaluation.

L-carnitine exists in several forms and is handled differently depending on route and formulation. Rather than specific amounts, the relevant conceptual factors include:

• Route — oral supplementation versus clinically administered injectable or IV forms
• Form — for example, L-carnitine versus acetyl-L-carnitine, which differ in properties
• Context — correcting a genuine deficiency differs fundamentally from general supplementation

Oral absorption of supplemental L-carnitine is relatively limited compared with dietary sources. This educational overview does not provide specific amounts, schedules, or protocols and does not constitute medical advice.

Carnitine is sold in three chemically distinct forms and under two entirely different regulatory regimes, and conflating them is the most common error in discussions of it.

The forms. The umbrella term "carnitine" covers L-carnitine, acetyl-L-carnitine, and propionyl-L-carnitine (NIH Office of Dietary Supplements). Supplement products range from about 3 mg to 5,000 mg per serving. Acetyl-L-carnitine is marketed for cognitive rather than metabolic claims; its bioavailability has not been well studied.

The prescription product. Levocarnitine is an approved medicine, not just a supplement. Carnitor is marketed as tablets, oral solution, a sugar-free oral solution, and an injection, and is indicated for primary systemic carnitine deficiency and for secondary carnitine deficiency arising from an inborn error of metabolism (Carnitor prescribing information). The label notes serious hypersensitivity reactions including anaphylaxis, laryngeal edema, and bronchospasm following intravenous levocarnitine, mostly in dialysis patients — the intravenous route is not a benign upgrade of the oral one.

Route changes how much arrives. Absorption of supplemental L-carnitine is about 14% to 18%, against 63% to 75% for carnitine obtained from food. Roughly 95% of total body carnitine is stored in heart and skeletal muscle, and a cooked 3-ounce beef steak supplies 42–122 mg. A capsule is therefore not a more concentrated version of dinner in any straightforward sense.

The combination that has actual data. Oral L-carnitine alone does not raise muscle carnitine content. Pairing 2 g of L-carnitine with 80 g of carbohydrate twice daily — the carbohydrate present to raise insulin — increased muscle total carnitine by 21% over 24 weeks, where the carbohydrate-only control showed no change (Wall et al., J Physiol 2011). That is a genuine, mechanistically motivated combination, and also a demanding one: 24 weeks and 160 g of daily carbohydrate.

Research on L-carnitine is strongest in the setting of genuine carnitine deficiency, where its role is well established. In healthy people, studies of L-carnitine for fat loss, body composition, and exercise performance have produced mixed and generally modest results.

Because the evidence differs sharply between deficiency and general supplemental use, claims should be interpreted in context. High-level overviews are not a substitute for critical appraisal of the primary literature.

For deeper dives on this compound, see:

• L-carnitine benefits and areas of interest
• L-carnitine side effects and safety context
• L-carnitine usage concepts (educational)
• L-carnitine research and evidence overview

Is L-carnitine a peptide? No. It is a single small molecule — (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate, formula C7H15NO3, molecular weight 161.2 (PubChem CID 10917). It is a quaternary ammonium compound the body synthesises in liver, kidney, and brain from the amino acids lysine and methionine, which is where "amino-acid derivative" comes from. Being made from amino acids is not the same as being a chain of them.

Does L-carnitine burn fat? Its transport role is real; the supplement claim is much weaker. Carnitine is the required carrier that moves long-chain fatty acids into mitochondria for oxidation — but that pathway is not normally rate-limited by carnitine availability in healthy, non-deficient people. A meta-analysis of 9 randomised trials in 911 participants found carnitine produced 1.33 kg more weight loss than control (95% CI −2.09 to −0.57) with a BMI reduction of 0.47 kg/m², and the effect significantly decreased the longer supplementation continued (Pooyandjoo et al., Obes Rev 2016). Roughly a kilogram, fading with time, is not what the marketing implies.

Can you even raise muscle carnitine by taking it? Not with capsules alone. In the study that finally demonstrated it, participants had to take 2 g of L-carnitine with 80 g of carbohydrate twice a day for 24 weeks to raise muscle total carnitine by 21%; the carbohydrate-only control group changed not at all (Wall et al., J Physiol 2011). Supplemental L-carnitine is also absorbed at only about 14–18%, versus 63–75% for dietary carnitine (NIH ODS).

What is the WADA infusion rule about? The volume, not the substance. L-carnitine appears nowhere on the WADA Prohibited List, and oral intake carries no anti-doping consequence. What is prohibited is method M2.2: intravenous infusions or injections totalling more than 100 mL per 12-hour period, outside legitimate hospital treatment, surgery, or clinical diagnostic investigation. Since IV carnitine is typically given in a saline bag well above that volume, the infusion itself is the violation even though nothing prohibited is in the bag. The Mengesha case described above shows how expensive that distinction becomes.

When is carnitine genuinely a medicine? In real deficiency. Levocarnitine (Carnitor) is FDA-approved for primary systemic carnitine deficiency — which presented in reported cases as recurrent Reye-like encephalopathy, hypoketotic hypoglycemia, and cardiomyopathy — and for secondary deficiency from an inborn error of metabolism (Carnitor prescribing information). Correcting a deficit is a categorically different proposition from topping up someone who already has normal stores.

What is the TMAO concern? Gut bacteria metabolise unabsorbed carnitine into trimethylamine, which the liver converts to trimethylamine-N-oxide. In the study that raised the issue, omnivorous participants produced more TMAO than vegans or vegetarians after ingesting L-carnitine, and among 2,595 adults undergoing cardiac evaluation, plasma carnitine predicted cardiovascular disease and major adverse cardiac events — but only in those with concurrently high TMAO (Koeth et al., Nat Med 2013). Mice fed carnitine developed more atherosclerosis, an effect abolished when their gut microbiota were suppressed. The clinical implications in humans remain debated rather than settled.

What are the side effects? Mostly gastrointestinal and mostly dose-related. Around 3 g/day can cause nausea, vomiting, abdominal cramps, diarrhea, and a fishy body odour — the latter a direct consequence of the same trimethylamine chemistry above. Muscle weakness has been described in people with uremia and seizures in those with seizure disorders. Intravenous levocarnitine has been associated with anaphylaxis, laryngeal edema, and bronchospasm, mostly in end-stage renal disease patients on dialysis.